Kensey Nash embolic filter:
This article was originally published in Clinica
Executive Summary
Kensey Nash has CE-marked for sale in Europe a third-generation version of its TriActiv system for preventing debris that has become dislodged during stenting from embolising downstream and causing adverse coronary events. The TriActiv ProGuard product is set to be launched for use in saphenous vein graft procedures by the end of March 2006. It incorporates several design enhancements compared with the earlier TriActiv platform, including a Local Flush and eXtraction technology that allows the system to better address branched anatomy and a smaller 6F compatible size, which is generally preferred by physicians, particularly in Europe, said the Exton, Pennsylvania firm.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.